Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: A U.S. trial of the GlycoMark assay

Diabetes Care

Volumn 27, Issue 8, 2004, Pages 1859-1865

  McGill, Janet B ^a   Cole, Thomas G ^a,c   Nowatzke, William ^a,c   Houghton, Shannon ^a   Ammirati, Erika B ^b   Gautille, Theresa ^b   Sarno, Mark J ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Vision Biotechnology Consulting   (United States)

^c Linco Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 ANHYDROSORBITOL; FRUCTOSAMINE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; ASSAY; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES CONTROL; DISEASE MARKER; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITION; PATIENT COUNSELING; PATIENT EDUCATION; PATIENT MONITORING;

ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DEOXYGLUCOSE; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LONGITUDINAL STUDIES; TIME FACTORS;

EID: 3342932958     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.8.1859     Document Type: Article

References (22)

1. Mokdad AH, Ford ES, Bowman BA, Nelson DE, Engelgau MM, Vinicor F, Marks JS: Diabetes trends in the U.S.: 1990-1998. Diabetes Care 23:1278-1283, 2000
2. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP: The continuing epidemics of obesity and diabetes in the United States. JAMA 286:1195-1200, 2001
3. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of the long-term complications of insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
4. U.K. Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
5. U.K. Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
6. Peterson CM, Jovanovic L: Glycosylated proteins in normal and diabetic pregnancy. Acta Endocrinol 277 (Suppl.):107-111, 1986
7. Buse JB, Freeman JLR, Edelman SV, Jovanovic L, McGill JB: Serum 1,5-anhydroglucitol (GlycoMark): a short-term glycemic marker. Diabetes Technol Ther 5:355-363, 2003
8. Pitkanen E: The serum protein pattern and the urinary polyol excretion in diabetic and in uremic patients. Clin Chim Acta 38:211-230, 1972
9. Pitkanen E: Occurrence of 1,5-anhydroglucitol in human cerebrospinal fluid. Clin Chim Acta 48:159-166, 1973
10. Yamanouchi T, Tachibana Y, Akanuma H, Minoda S, Shinohara T, Moromizato H, Miyashita H, Akaoka I: Origin and disposal of 1,5-anhydroglucitol, a major polyol in the human body. Am J Physiol 236:E268-E273, 1992
11. Kametani S, Hashimoto Y, Yamanouchi T, Akanuma Y, Akanuma H: Reduced renal reabsorption of 1,5-anhydroglucitol in diabetic rats and mice. J Biochem 102:1599-1607, 1987
12. Akanuma Y, Ogawa K, Yamanouchi T, Mashiko S, Oka Y, Kosaka K, Akanuma H: Decreased plasma 1,5-anhydroglucitol in diabetic patients (Abstract). Diabetes 30 (Suppl. 1):124A, 1981
13. Yoshioka S, Saitoh S, Negishi C, Fujisawa T, Fujimori A, Takatani O, Imura M, Funabashi M: Variations of 1-deoxyglucose (1,5-anhydroglucitol) content in plasma from patients with insulin-dependent diabetes mellitus. Clin Chem 29:1396-1398, 1983
14. Yamanouchi T, Minoda S, Yabuuchi M, Akanuma Y, Akanuma H, Miyashita H, Akaoka I: Plasma 1,5-anhydroglucitol as new clinical marker of glycemic control in NIDDM patients. Diabetes 38:723-729, 1989
15. Fukumura Y, Tajima S, Oshitani S, Ushijima Y, Kobayashi I, Hara F, Yamamoto S, Yabuuchi M: Fully enzymatic method for determining 1,5-anhydro-D-glucitol in serum. Clin Chem 40:2013-2016, 1994
16. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 25 (Suppl. 1):5-20, 2002
17. Yamanouchi T, Ogata N, Tagaya T, Kawasaki T, Sekino N, Funato H, Akaoka I, Miyashita H: Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycemic control. Lancet 347:1514-1518, 1996
18. Yamanouchi T, Akanuma Y, Toyota T, Kuzuya T, Kawai T, Kawazu S, Yoshioka S, Kanazawa Y, Ohta M, Baba S, Kosaka K: Comparison of 1,5-anhydroglucitol, A1C, and fructosamine for detection of diabetes mellitus. Diabetes 40:52-57, 1991
19. Yamanouchi T, Akanuma Y: Serum 1,5-anhydroglucitol (1,5-AG): new clinical marker for glycemic control. Diabetes Res Clin Pract 24 (Suppl.):S261-S268, 1994
20. Stickle D, Turk J: A kinetic mass balance model for 1,5-anhydroglucitol: applications to monitoring of glycemic control. Am J Physiol 273:E821-E830, 1997
21. Kishimoto M, Yamasaki Y, Kubota M, Arai K, Morishima T, Kawamori R, Kamata T: 1,5-anhydro-D-glucitol evaluates daily glycemic excursions in well-controlled NIDDM. Diabetes Care 18:1156-1159, 1995
22. Sone H, Okuda Y, Yamaoka T, Kawakami Y, Odawara M, Matsushima T, Kawai K, Yamashita K: Predicting long-term glycemic control of post-educational type II diabetic patients by evaluating serum 1,5-anhydroglucitol levels. Diabetes Res Clin Pract 34:83-88, 1996